Clinical Trial Update: 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients [Phase 2]

View source ↗

Summary

A 24-month open-label Phase 2 study of inotersen in transthyretin amyloid cardiomyopathy has been terminated. The trial was sponsored by Brigham and Women's Hos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Inotersen (inotersen)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Amyloidosis | Phase 2 | Status: TERMINATED